Fall Patient Insight Webinars from the Bladder Cancer Advocacy Network

Article

The Bladder Cancer Advocacy Network has announced its fall series of webinars, featuring bladder cancer experts on a variety of topics. The webinars are relevant to people with bladder cancer, caregivers, family, and friends:

The Bladder Cancer Advocacy Network has announced its fall series of webinars, featuring bladder cancer experts on a variety of topics. The webinars are relevant to people with bladder cancer, caregivers, family, and friends:

The New Normal After Bladder Removal Surgery: Part 2

Tuesday, October 21, 8-9 PM EDT

Presented by:

Tracy M. Downs, MD

Associate Professor, Urology

Director, Bladder Cancer and Intravesicle Programs

University of Wisconsin

Deborah Hensley, BSN, RN, CURN

Department of Urology

UT Southwestern Medical Center

Topics for this webinar include: recovery and what to expect after bladder removal surgery; preventing complications; deciding on a diversion, and recognizing what’s normal after surgery.

Click here to register.

What do you wish you had known before bladder removal surgery?

Tuesday, November 4, 8 PM EST

Presented by:

Jonathan L Wright, MD, MS, FACS

Department of Urology,

University of Washington School of Medicine,

Seattle Cancer Care Alliance

Topics for this webinar include: different urinary diversions and information from survivors on what they wish they had known before bladder surgery.

Click here to register.

Bladder Cancer Tests, Diagnosis & Screening

Thursday, November 13, 8 PM ET

Presented by:

Yair Lotan, MD

Holder of the Helen J. and Robert S. Strauss

Professorship in Urology

UT Southwestern Medical Center

Topics for this webinar include: what patients should know about tests used to diagnose and check for recurrence of bladder cancer and follow up and surveillance recommendations.

For more information, call 301-215-9099 or email: webinars@bcan.org

Recent Videos
Brenda Martone
Arash Rezazadeh Kalebasty
Leapman
Laura Wood on the Integration of Avelumab, Erdafitinib, and Enfortumab Vedotin into Urothelial Cancer Care
Related Content
© 2024 MJH Life Sciences

All rights reserved.